MDL 19301
目录号 : GC31908
MDL19301是一种非甾体抗炎剂。
Cas No.:89388-38-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
MDL 19301 is a nonsteroidal, anti-inflammatory agent.
Oral administration of MDL 19301 inhibits rat paw edema induced by carrageenan (ED30=4.8 mg/kg) or an Arthus reaction (ED30=8.2 mg/kg p.o.). The oral dose which induces gastric ulceration in 50% of fasted rats is greater than 1,000 mg/kg, demonstrating a more favorable therapeutic ratio than conventional nonsteroidal anti‐inflammatory agents. The anti-inflammatory activity of MDL 19301, but not that of MDL 16,861, is attenuated by co-administration of an inhibitor of drug metabolite (SKF525A). This suggests that MDL 19301 is a prodrug of MDL 16,861 and this phenomenon would explain its lack of ulcerogenicity. Additional anti-inflammatory properties of MDL 19301 include inhibition of carrageenan pleurisy, adjuvant arthritis, and HOAc-induced writhing. Other pharmacological data indicate that MDL 19301 administration results in inhibition of prostaglandin synthesis; inhibition of arachidonic acid-induced, but not prostaglandin-E2-induced, diarrhea in mice; and inhibition of ex vivo arachidonic-acid-induced, but not ADP-induced, rat platelet aggregation. MDL 19301 and MDL 16,861 are unexpectedly weak antipyretic agents in rats[1].
[1]. NS Doherty, et al. Pharmacological properties of MDL 19,301: A novel, nonsteroidal, anti‐inflammatory agent. Drug Dev Res 1989 16(1) 31-44
| Cas No. | 89388-38-5 | SDF | |
| Canonical SMILES | CCCCCCC1=CC=C(/N=C2SCCS\2)C=C1 | ||
| 分子式 | C15H21NS2 | 分子量 | 279.46 |
| 溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.5783 mL | 17.8916 mL | 35.7833 mL |
| 5 mM | 0.7157 mL | 3.5783 mL | 7.1567 mL |
| 10 mM | 0.3578 mL | 1.7892 mL | 3.5783 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。